Becton, Dickinson and Company $BDX Shares Sold by Exencial Wealth Advisors LLC

Key Points

• Exencial Wealth Advisors cut its stake in Becton, Dickinson by 41.8%, selling 28,117 shares and leaving 39,195 shares valued at $7.61 million; institutional investors own about 86.97% of the company.
• Becton, Dickinson reported quarterly EPS of $2.91 (beat) but revenue of $4.49 billion missed estimates, and the company set FY 2026 guidance of $12.35–$12.65 EPS.
• The stock is trading around $150.13, below its 200-day average, while analysts have an average "Hold" rating with a $189.08 price target, and director Bertram L. Scott recently sold 953 shares at $182.61.

Exencial Wealth Advisors LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 41.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,195 shares of the medical instruments supplier's stock after selling 28,117 shares during the period. Exencial Wealth Advisors LLC's holdings in Becton, Dickinson and Company were worth $7,607,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Crux Wealth Advisors increased its position in Becton, Dickinson and Company by 0.8% during the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier's stock worth $1,222,000 after buying an additional 49 shares during the period. Camelot Portfolios LLC increased its position in Becton, Dickinson and Company by 1.5% during the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier's stock worth $688,000 after buying an additional 54 shares during the period. McElhenny Sheffield Capital Management LLC increased its position in Becton, Dickinson and Company by 3.6% during the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier's stock worth $309,000 after buying an additional 55 shares during the period. Phillips Wealth Planners LLC increased its holdings in shares of Becton, Dickinson and Company by 2.7% in the third quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier's stock valued at $430,000 after purchasing an additional 58 shares during the period. Finally, PDS Planning Inc increased its holdings in shares of Becton, Dickinson and Company by 3.6% in the fourth quarter. PDS Planning Inc now owns 1,678 shares of the medical instruments supplier's stock valued at $326,000 after purchasing an additional 58 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director owned 36,763 shares of the company's stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BDX. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a report on Friday, April 10th. They issued a "neutral" rating and a $167.00 target price on the stock. Wells Fargo & Company dropped their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 10th. TD Cowen boosted their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a "hold" rating in a report on Wednesday, February 11th. Piper Sandler dropped their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a "neutral" rating on the stock in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. dropped their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating on the stock in a report on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $189.08.

Becton, Dickinson and Company Trading Down 1.3%

Shares of BDX stock opened at $150.13 on Tuesday. The business's fifty day moving average price is $162.67 and its 200 day moving average price is $182.74. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The firm has a market capitalization of $42.75 billion, a PE ratio of 24.49, a P/E/G ratio of 10.82 and a beta of 0.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the prior year, the company posted $3.43 earnings per share. Becton, Dickinson and Company's quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.56 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback program on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.